期刊
CURRENT PHARMACEUTICAL DESIGN
卷 10, 期 12, 页码 1355-1363出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612043384826
关键词
blood-brain barrier; drug efflux; drug delivery; fatty acylation; nanogel; nanoparticles; pluronic block copolymers; poloxamer
资金
- NINDS NIH HHS [R01 NS036229-08, R01 NS036229-09, R01 NS036229-05A2, R01 NS051334-02, R01 NS036229-04, R01 NS051334-03, NS36229, R01 NS036229, R01 NS036229-07, R01 NS036229-06, R01 NS051334-01A1, R01 NS051334, R01 NS036229-03] Funding Source: Medline
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036229, R01NS051334] Funding Source: NIH RePORTER
The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore. discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic((R)) block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves artificial hydrophobization of peptides and proteins that facilitates the delivery of these peptides and proteins across BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据